+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gingivitis - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • February 2022
  • Region: Global
  • DelveInsight
  • ID: 4330927
The publisher’s, “Gingivitis - Pipeline Insight, 2022,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gingivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Gingivitis Understanding


Gingivitis: Overview

Gingivitis is a form of gum disease that happens when plaque, a naturally-occurring sticky film containing bacteria, builds up on teeth and causes the inflammation of the surrounding gum tissue. Plaque produces toxins that irritate the gums. This can cause the gums to become inflamed, making them red or puffy, or causing them to bleed. This harmful plaque bacteria can even lead to issues beyond gingivitis like weakened tooth enamel. Even with regular brushing, it's important to make sure you’re taking care of your gum line, because a healthy mouth starts there

'Gingivitis - Pipeline Insight, 2022' report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gingivitis pipeline landscape is provided which includes the disease overview and Gingivitis treatment guidelines. The assessment part of the report embraces, in depth Gingivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gingivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Gingivitis R&D. The therapies under development are focused on novel approaches to treat/improve Gingivitis.

Gingivitis Emerging Drugs Chapters

This segment of the Gingivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gingivitis Emerging Drugs


Mycobactovir: LTN Pharm

Mycobactovir is a Chitin synthase inhibitors being developed by LTN Pharma. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patients with gingivitis.

AMY 101: Amyndas Pharmaceuticals

AMY 101 is a Complement C3 inhibitor being developed by Amyndas Pharmaceuticals. The drug is currently in phase 2 stage of clinical trial evaluation for the treatment of patients with gingivitis.

Further product details are provided in the report……..

Gingivitis: Therapeutic Assessment

This segment of the report provides insights about the different Gingivitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Gingivitis

There are approx. 3+ key companies which are developing the therapies for Gingivitis. The companies which have their Gingivitis drug candidates in the most advanced stage, i.e. phase II include, Amyndas Pharmaceuticals.

Phases


The publisher’s report covers around 3+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration


Gingivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gingivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gingivitis therapeutic drugs key players involved in developing key drugs.

Gingivitis Report Insights

  • Gingivitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Gingivitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Gingivitis drugs?
  • How many Gingivitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gingivitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gingivitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gingivitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • LTM Pharm
  • Amyndas Pharmaceuticals
  • Aphios
  • Biomedical Development Corporation
  • Colgate Palmolive

Key Products

  • Mycobactovir
  • AMY 101
  • Research programme: marine anti-plaque compounds
  • Iodine-based oral rinse

Table of Contents

IntroductionExecutive Summary
Gingivitis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
  • Gingivitis - The Publisher’s Analytical Perspective

Mid Stage Products (Phase II)
  • Comparative Analysis

AMY101: Amyndas Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Early Stage Products (Phase I)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
  • Drug profiles in the detailed report

Inactive Products
  • Comparative Analysis
  • Gingivitis Key Companies
  • Gingivitis Key Products
  • Gingivitis- Unmet Needs
  • Gingivitis- Market Drivers and Barriers
  • Gingivitis- Future Perspectives and Conclusion
  • Gingivitis Analyst Views
  • Gingivitis Key Companies
  • Appendix

List of Tables
Table 1 Total Products for Gingivitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Gingivitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • LTM Pharm
  • Amyndas Pharmaceuticals
  • Aphios
  • Biomedical Development Corporation
  • Colgate Palmolive